NCT01236001

Belgian Drug-utilization Study to Evaluate the Use of VIMPAT® as Adjunctive Treatment of Partial Onset Seizures in Subjects Aged 16 and Older

Multi-center, Observational, Drug-utilization Study in Belgium to Evaluate the Use of VIMPAT® in Clinical Practice as Adjunctive Treatment of Partial Onset Epilepsy in Subjects Aged 16 and Older.

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 192 (actual)
• Sponsor: UCB Pharma · Industry
• Sex: All
• Age: 16 Years
• Healthy volunteers: Not accepted

Summary

Observational study at the request of the Belgian Institut National d'Assurance Maladie-Invalidité / Rijksinstituut voor Ziekte-en Invaliditeits Verzekering INAMI/RIZIV: * type of patient treated with VIMPAT® * VIMPAT® dose * Effect of VIMPAT® on evolution of seizure control * Persistence rate at 6 months in terms of treatment duration * Discontinuation rate * Description of any changes in other epilepsy therapies * Safety and tolerability

Conditions

• Seizures

Interventions

Type	Name	Description
DRUG	Lacosamide

Timeline

• Start date: 2010-09-01
• Primary completion: 2012-03-01
• Completion: 2012-03-01
• First posted: 2010-11-08
• Last updated: 2013-08-08
• Results posted: 2013-08-08

Locations

17 sites across 1 country: Belgium